Latest news with #Coric
Time of India
20-05-2025
- Sport
- Time of India
Top seed Borna Coric stunned by wildcard Titouan Droguet in French Open qualifier
Droguet's Breakthrough Performance Live Events Wide Open Qualifying Draw (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel There was a dramatic upset on Court Suzanne-Lenglen when top seed Borna Coric was eliminated in the first round of French Open qualifying by French wildcard Titouan Droguet , who won 7-5, 6-7, 7-6 in an engrossing three-set seed Coric, No. 83 and former No. 12 was heavily favored to cruise through qualifying, having met with a 26-8 win-loss record this year and four Challenger titles, two of them on clay. His recent playing record and Grand Slam experience also made him the heavy favorite, but he found it difficult to get his rhythm going against the bold after coming back to win the second set in a tiebreak, Coric was not able to resist the Frenchman's consistent aggression in the deciding set. Ranked No. 232, Droguet kept his cool in front of a raucous home crowd, winning the final set tiebreak and securing a spot in the second Droguet, this win is the largest of his career and a coming-out party on one of tennis's largest stages. The 23-year-old, who had never faced Coric previously, equaled the Croatian in consistency from the baseline and seized upon important moments, especially in the intense third momentum firmly on his side, Droguet will return to the courts on Thursday, May 22, for a second-round qualifying match against fellow Frenchman Arthur Gea . Gea, also a wildcard, advanced after defeating Alexander Blockx in his own opening round. The all-French encounter promises to be a dynamic battle, with both players eyeing a breakthrough at Roland Garros Following the first seed's early elimination, Coric's loss expands the field for the men's qualifiers, creating additional opportunities for other aspirants and lower-seeded players. The surprise serves as a reminder of how difficult and unpredictable Grand Slam qualifying is, with any match having the potential to completely change the course of Score: Titouan Droguet defeated Borna Coric 7-5, 6-7, 7-6
Yahoo
25-04-2025
- Business
- Yahoo
Biohaven stock slides on withdrawal of European marketing application
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Biohaven lost close to $400 million in market value Friday on news that the Connecticut-based drug developer had withdrawn an application to get one of its most advanced experimental therapies approved in Europe. The company first asked the European Medicines Agency for approval in late 2023, believing enough evidence had been gathered to show its drug, tentatively branded as Dazluma, is effective at treating 'spinocerebellar ataxia,' a type of rare genetic disorder that impairs nerve cells. Once in the body, the drug is designed to break down into riluzole, a molecule already approved in Europe and the U.S. for patients with ALS. On Friday, the EMA revealed that Biohaven withdrew its application on March 24. The agency's main drug review committee said, by that time, it had some concerns about Dazluma, and its provisional opinion was a marketing authorization couldn't be granted. The committee explained that not only was Dazluma's effectiveness not proven, but Biohaven had requested the drug receive a 'new active substance' classification, which comes with significant commercial benefits. EMA staff weren't convinced the drug is significantly different than plain riluzole. In an emailed statement, Biohaven CEO Vlad Coric said his company ultimately pulled the approval application once it became clear the committee didn't intend on bestowing that classification. Coric added that Biohaven is committed to quickly providing the committee with either further arguments, 'appropriate data,' or both, and plans to do so in approximately three months. The company 'remains committed to the Dazluma program and plans to resubmit to EMA this year once the data is generated to respond to' the new active substance issue. "In our view, we view this as a speed bump, but not ultimately a roadblock, on the [European approval] front," wrote Charles Duncan, an analyst for Cantor Fitzgerald, in a note to clients. Biohaven shares were down roughly 16% Friday afternoon, to trade around $19.50 apiece. Meanwhile, the company has also submitted an application to the Food and Drug Administration, and an approval verdict is expected sometime between July and the end of September. To Leonid Timashev, an analyst at the investment bank RBC Capital Markets, the withdrawal in Europe adds risk to the U.S. review, as it 'calls into question whether the FDA would be similarly strict.' Biohaven investors have 'been more bearish lately, and questions have focused on what can drive a turnaround in shares,' he wrote in a note to clients. Most believe FDA approval is 'critical to helping the stock recover. We believe this puts additional pressure on the news, and explains the outsized stock move.' In late 2022, Biohaven completed selling off its portfolio of migraine medications to Pfizer for nearly $12 billion. Since then, the new company has been trying to find its next success story, amassing a research pipeline with more than a dozen experimental medicines targeting a range of disease categories, from oncology to immunology to neuroscience. Yet a couple of those medicines recently hit setbacks in clinical testing. Investor confidence in the pipeline seems to have waned over the past year, with Biohaven shares now having lost two-thirds of their value from when they peaked at roughly $58 in March 2024. Recommended Reading After setback, Biohaven to seek approval of neurological disorder drug Sign in to access your portfolio
![2025 Mutua Madrid Open: Arnaldi [44th] vs. Coric [104th] Prediction, Odds and Match Preview](/_next/image?url=https%3A%2F%2Fwww.gannett-cdn.com%2Fauthoring%2Fimages%2FDataSkriveSportsbookWire%2F2025%2F04%2F16%2FSSBK%2F83116869007-14991234.jpeg%3Fauto%3Dwebp%26crop%3D1199%2C676%2Cx0%2Cy73%26format%3Dpjpg%26width%3D1200&w=3840&q=100)
![2025 Mutua Madrid Open: Arnaldi [44th] vs. Coric [104th] Prediction, Odds and Match Preview](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fusatoday.com.png&w=48&q=75){kind=small}
USA Today
23-04-2025
- Sport
- USA Today
2025 Mutua Madrid Open: Arnaldi [44th] vs. Coric [104th] Prediction, Odds and Match Preview
2025 Mutua Madrid Open: Arnaldi [44th] vs. Coric [104th] Prediction, Odds and Match Preview Matteo Arnaldi (No. 44 ranking) will take on Borna Coric (No. 104) in the Round of 128 of the Mutua Madrid Open on Thursday, April 24. Arnaldi is the favorite (-175) in this match against the underdog Coric (+135). Tennis odds courtesy of BetMGM Sportsbook. Odds updated Wednesday at 2:35 AM ET. For a full list of sports betting odds, access USA TODAY Sports Betting Scores Odds Hub. Matteo Arnaldi vs. Borna Coric matchup info Tournament: Mutua Madrid Open Mutua Madrid Open Round: Round of 128 Round of 128 Date: Thursday, April 24 Thursday, April 24 Court Surface: Clay Watch the Tennis Channel and more sports on Fubo! Arnaldi vs. Coric Prediction Based on the implied probility from the moneyline, Arnaldi has a 63.6% to win. Arnaldi vs. Coric Betting Odds Arnaldi vs. Coric matchup performance & stats
USA Today
23-04-2025
- Sport
- USA Today
How to Watch Matteo Arnaldi vs. Borna Coric at the 2025 Mutua Madrid Open: Live Stream, TV Channel
How to Watch Matteo Arnaldi vs. Borna Coric at the 2025 Mutua Madrid Open: Live Stream, TV Channel Matteo Arnaldi (No. 44 ranking) will face Borna Coric (No. 104) in the Round of 128 of the Mutua Madrid Open on Thursday, April 24. Arnaldi's most recent competition was on April 14, 2025 at the Barcelona Open Banc Sabadell, when he fell 6-3, 3-6, 2-6 to Sebastian Korda in the Round of 32. Coric heads into this match following a two-set victory over Gabriel Diallo (6-3, 7-6) in his last match on Tuesday in the qualifying round. Watch Tennis Channel on Fubo! Matteo Arnaldi vs. Borna Coric: live stream info & TV channel Tournament: Mutua Madrid Open Mutua Madrid Open Round: Round of 128 Round of 128 Date: Thursday, April 24 Thursday, April 24 Live Stream: Watch Tennis Channel on Fubo Watch Tennis Channel on Fubo Court Surface: Clay Matteo Arnaldi vs. Borna Coric matchup stats In eight tournaments on clay over the past 12 months, Arnaldi has gone 6-8. Arnaldi has won 72.5% of his service games on clay over the past year and 27.6% of his return games. Arnaldi has converted 42.3% of his break-point opportunities on clay (47 of 111) over the past year. Arnaldi was eliminated by Korda (6-3, 3-6, 2-6) on April 14 in the Round of 32 of his last tournament, the Barcelona Open Banc Sabadell. Coric has taken part in five tournaments on clay over the past year, posting a 4-4 record on that surface. Coric has a 78.4% winning percentage in service games while playing on clay surfaces, and a 22.1% winning percentage in return games. On clay surfaces Coric has won 43.6% of break points, 17 out of 39, to rank 154th. In the Barcelona Open Banc Sabadell, Coric's previous tournament, he squared off against No. 123-ranked Ethan Quinn in the Qualification Final on April 13 and was defeated 6-2, 4-6, 3-6. Arnaldi vs. Coric futures odds Tennis odds courtesy of Tipico Sportsbook. Odds updated Tuesday at 6:57 PM ET. Arnaldi Odds to Win the 2025 Mutua Madrid Open: +15000 +15000 Coric Odds to Win the 2025 Mutua Madrid Open: +20000 Tennis odds courtesy of BetMGM Sportsbook. Odds updated Tuesday at 6:57 PM ET. For a full list of sports betting odds, access USA TODAY Sports Betting Scores Odds Hub.
Yahoo
31-01-2025
- Business
- Yahoo
KPIT Technologies Ltd (BOM:542651) Q3 2025 Earnings Call Highlights: Strong Revenue and Profit ...
Revenue Growth: 20.7% year-to-date growth over last year Q3 FY25. Quarterly Revenue Growth: 17.4% in constant currency, 18.1% year-on-year. EBITDA Margin: 21.1% compared to 20.8% last year. Profit Growth: 38% year-to-date over the same period last year; 20.4% year-on-year for the quarter. Cash Generation: Increased from INR9.6 billion last quarter to INR14.2 billion this quarter. Days Sales Outstanding (DSO): 42 days, typically around 45 days. Interim Dividend: INR2.5 per share compared to INR2.1 per share last year. Deal Wins: USD 236 million during the quarter. Warning! GuruFocus has detected 1 Warning Sign with BOM:542651. Release Date: January 29, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. KPIT Technologies Ltd (BOM:542651) reported a strong year-to-date revenue growth of 20.7% and profit growth of 38% over the same period last year. The company has seen significant cash generation, with cash increasing from INR9.6 billion last quarter to INR14.2 billion this quarter. KPIT Technologies Ltd (BOM:542651) has maintained a low attrition rate, about half of the industry average, indicating strong employee retention. The company has a robust pipeline, which has increased by over 20% during the quarter, driven by large deals and broad-based client engagement. KPIT Technologies Ltd (BOM:542651) continues to invest in AI and cybersecurity, enhancing its technological capabilities and future readiness. There is a slowdown in global auto volumes, which could impact demand from clients, particularly in the US and Europe. The transition from electric vehicles (EVs) to hybrids and other alternatives by OEMs may pose challenges in terms of revenue adjustments. The company faces potential risks from the merger of key clients, such as Honda and Nissan, which could impact existing work and growth prospects. KPIT Technologies Ltd (BOM:542651) has experienced an increase in other expenses, which rose by 11% sequentially, impacting overall profitability. The company is cautious about mergers and acquisitions, opting not to pursue QIP in the short term, which may limit expansion opportunities. Q: Between the US and Europe, where do you see demand from clients coming back sooner based on your conversations? Also, how does the shift from EVs to hybrids impact your business with OEMs? A: Demand recovery is led by Europe, followed by the Americas and Asia. The shift to hybrids and other propulsion methods presents a great opportunity for KPIT, as we are involved in both battery electric and hybrid solutions. This trend is positive for us across various markets, including the US, Japan, and India. (Sachin Tikekar, President, Joint Managing Director, Executive Director) Q: Can you provide an update on the Coric initiative and when it might start contributing to revenue? A: We are on track with Coric, having secured a significant OEM client and are in advanced discussions with another European OEM. We expect Coric to contribute to revenue in FY26. (Kishor Patil, CEO, Co-Founder, Managing Director, Executive Director) Q: How do you see the deal pipeline shaping up in the upcoming quarters? A: We have seen significant improvement in deal closures and pipeline build-up, with opportunities across geographies and sub-verticals. We expect this trend to continue, driven by passenger cars, trucks, and off-highway vehicles, as well as collaborations with semiconductor companies. (Sachin Tikekar, President, Joint Managing Director, Executive Director) Q: Regarding the potential Honda-Nissan merger, do you foresee any risks to your existing work with Honda? A: We view the merger as a positive opportunity, potentially expanding our work with Nissan. We are a critical partner for Honda, and this merger could enhance our engagement with both companies. (Sachin Tikekar, President, Joint Managing Director, Executive Director) Q: How are you addressing the margin impact from the growth in ROW (Rest of World) geographies, which are typically lower margin? A: We do not see a negative impact on profitability from ROW growth. We are focusing on AI and automation to improve productivity and are shifting our revenue mix towards higher-margin areas like licenses and outcome-based revenues. (Kishor Patil, CEO, Co-Founder, Managing Director, Executive Director) For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
